14 July 2021

in June 2021 ZonMw announced which 7 consortia could start within the PSIDER program in. Radboudumc researchers were part of these 7 consortia. With a total budget of 3.5 to 4 million, the consortia will work together in a multidisciplinary setting for the next 5 to 6 years. They all will contribute to either the creation of alternatives to embryos or the development of knowledge about disease mechanisms and the treatment of serious hereditary disorders.

Our researchers receive ZonMw funding for PSIDER program are:

  • Michiel Vermeulen and Klaas Mulder ​from Faculty of Science of Radboud University and is part of the interfaculty research institute RIMLS.
    • Title: From pluripotent stem cells to prime editing gene therapy for inherited cardiomyopathies (link)

 

  • Nael Nadif Kasri (Radboud University)​
    • Title: BRAINMODEL: standardized, IPSC-based medicine for immediate application in monogenic neurodevelopmental disorders

Read more (Dutch)

Related news items


How are the Dutch Olympians prepared for the heat and humidity of Tokyo?

22 July 2021

Personal heat preparedness advice for Dutch Olympic athletes

read more

Nijmegen literally puts Digital Health on the map Flourishing ecosystem gets its own interactive overview

22 July 2021

Digital Health is thriving in the Nijmegen region, where it contributes to better care and health and also creates jobs. To bring developers and end users even closer together, The Economic Board and the Radboudumc are introducing the Interactive Digital Health map.

read more

Jeroen de Baaij Appointed associate professor

21 July 2021

Jeroen de Baaij, from the department of Physiology, has been appointed associate professor Kidney Physiology as of 1 August 2021.

read more

Michiel Vermeulen and Klaas Mulder receive funding from ZonMw for a collaborative project using stem cell-based models

15 July 2021

Michiel Vermeulen and Klaas Mulder, theme Cancer development and immune defense, receive funding from ZonMw for a collaborative project to develop a stem cell based model to study early human embryogenesis.

read more

Launch of UNITE4TB partnership marks a new era in Tuberculosis treatment development

15 July 2021

The partnership will accelerate the development of new Tuberculosis (TB) drug regimens as part of the Innovative Medicines Initiative (IMI), a public-private European Research & Development Consortium

read more